Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Mallinckrodt
Moodys
Merck
Johnson and Johnson

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

ENTEREG Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Entereg patents expire, and what generic alternatives are available?

Entereg is a drug marketed by Cubist Pharms and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has twenty patent family members in fourteen countries.

The generic ingredient in ENTEREG is alvimopan. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alvimopan profile page.

US ANDA Litigation and Generic Entry Outlook for Entereg

A generic version of ENTEREG was approved as alvimopan by WATSON LABS TEVA on December 19th, 2019.

  Start Trial

Drug patent expirations by year for ENTEREG
Drug Prices for ENTEREG

See drug prices for ENTEREG

Recent Clinical Trials for ENTEREG

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The Cleveland ClinicPhase 4
University of California, San DiegoPhase 2
University of Puerto RicoPhase 4

See all ENTEREG clinical trials

Pharmacology for ENTEREG
Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists
Paragraph IV (Patent) Challenges for ENTEREG
Tradename Dosage Ingredient NDA Submissiondate
ENTEREG CAPSULE;ORAL alvimopan 021775 2017-06-16

US Patents and Regulatory Information for ENTEREG

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Mallinckrodt
Moodys
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.